Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology

Takeda Pharmaceutical Co. Ltd. has discontinued preclinical R&D work in the area of adeno-associated virus (AAV) gene therapies, as well as research and preclinical efforts in rare hematology.

The decision was prompted by a desire to focus resource on its core therapeutic areas and candidates already in late-stage development, a spokesperson from the major Japanese firm told Scrip